ABVC ABVC BioPharma, Inc. Stock Quote

ABVC [NASD]

Index	-	P/E	-	EPS (ttm)	-0.51	Insider Own	46.08%	Shs Outstand	25.05M	Perf Week	-15.10%
Market Cap	59.45M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	16.34M	Perf Month	-21.80%
Income	-12.80M	PEG	-	EPS next Q	-	Inst Own	1.50%	Short Float	0.47%	Perf Quarter	-17.13%
Sales	0.40M	P/S	148.62	EPS this Y	-3.20%	Inst Trans	-	Short Ratio	1.23	Perf Half Y	-39.18%
Book/sh	0.35	P/B	5.94	EPS next Y	-	ROA	-112.80%	Target Price	9.50	Perf Year	-62.18%
Cash/sh	0.21	P/C	10.08	EPS next 5Y	-	ROE	-239.40%	52W Range	1.95 - 11.69	Perf YTD	-38.64%
Dividend	-	P/FCF	-	EPS past 5Y	-8.30%	ROI	-120.50%	52W High	-82.21%	Beta	0.57
Dividend %	-	Quick Ratio	2.60	Sales past 5Y	-	Gross Margin	98.60%	52W Low	6.67%	ATR	0.19
Employees	28	Current Ratio	2.60	Sales Q/Q	300.00%	Oper. Margin	-	RSI (14)	38.50	Volatility	9.76% 7.94%
Optionable	No	Debt/Eq	0.18	EPS Q/Q	-115.60%	Profit Margin	-	Rel Volume	0.21	Prev Close	2.09
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	63.03K	Price	2.08
Recom	-	SMA20	-12.52%	SMA50	-15.52%	SMA200	-26.27%	Volume	13,402	Change	-0.48%

May-16-22 05:46PM	ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results GlobeNewswire -5.78%
03:25PM	WallachBeth Capital Announces Completion of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering PR Newswire
May-13-22 08:30AM	ABVC BioPharma Engages the FreeMind Group to Support Grant Funding GlobeNewswire +6.13%
May-12-22 09:00AM	WallachBeth Capital Announces Pricing of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering PR Newswire -13.47%
08:30AM	ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering GlobeNewswire
May-10-22 08:30AM	ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated GlobeNewswire +8.24%
May-05-22 08:30AM	ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process GlobeNewswire
May-03-22 08:30AM	ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed GlobeNewswire
Apr-28-22 08:30AM	ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study GlobeNewswire
Apr-26-22 08:30AM	ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting GlobeNewswire
Mar-31-22 04:18PM	ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results GlobeNewswire
Mar-23-22 09:25AM	ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference GlobeNewswire
Mar-08-22 06:15AM	ABVC: Lead Products Move Closer To Potential Approval; Important Clinical Studies Advancing Zacks Small Cap Research
Feb-02-22 08:00AM	ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study GlobeNewswire
Jan-05-22 08:30AM	ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites GlobeNewswire
Dec-22-21 08:30AM	ABVC BioPharmas Vitreous Substitute Vitargus Presented at 14th APVRS Congress GlobeNewswire
Dec-15-21 08:30AM	ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award GlobeNewswire +8.85%
Dec-10-21 01:38PM	Why ABVC BioPharma Shares Are Trading Higher On Friday? Benzinga +5.14%
05:17AM	ABVC: Moving Forward on Several 2022 Goals to Advance Growth Strategy Zacks Small Cap Research
Dec-09-21 08:30AM	ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement GlobeNewswire
Nov-15-21 04:33PM	ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results GlobeNewswire +7.23%
Nov-11-21 09:00AM	ABVC Biopharma Receives Additional $4,245,000 from Exercise of Warrants, Total Capital from Public Offering Increases to Approx. $11.1M GlobeNewswire
Nov-03-21 11:18AM	10 Best Stocks For Day Trading Insider Monkey -7.42%
Nov-02-21 06:18AM	What Percentage Of ABVC BioPharma, Inc. (NASDAQ:ABVC) Shares Do Insiders Own? Simply Wall St. -26.20%
Nov-01-21 11:32AM	ABVC Stock: The Social Media Chatter That Has ABVC BioPharma Shooting 250% Higher Today InvestorPlace +137.40%
10:51AM	What's Going On With ABVC BioPharma's Stock Today? Benzinga
10:21AM	Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention Bloomberg
07:28AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday InvestorPlace
07:03AM	28 Stocks Moving in Monday's Pre-Market Session Benzinga
Oct-27-21 08:30AM	Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites GlobeNewswire
Oct-15-21 12:05PM	33 Stocks Moving In Friday's Mid-Day Session Benzinga +10.16%
07:03AM	22 Stocks Moving in Friday's Pre-Market Session Benzinga
Oct-12-21 08:30AM	ABVC BioPharma Restructures Joint Venture to Expand Access to Early-Stage Research GlobeNewswire +10.09%
Sep-13-21 08:30AM	ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study GlobeNewswire -6.54%
Sep-01-21 03:54PM	Why ABVC BioPharma Shares Are Trading Higher Today Benzinga +23.79%
08:30AM	ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments GlobeNewswire
Aug-30-21 08:30AM	ABVC BioPharma Report Updated by Zacks/SCR GlobeNewswire +7.07%
Aug-26-21 08:30AM	ABVC BioPharma Provides Vitargus® Update GlobeNewswire +16.67%
05:00AM	ABVC: Company Continues to Advance Lead Assets & Earlier Stage Candidates Zacks Small Cap Research
Aug-12-21 08:27AM	ABVC BioPharma Reports Second Quarter 2021 Results GlobeNewswire -24.30%
Aug-06-21 08:30AM	WallachBeth Capital Announces the Completion of an Underwritten Public Offering of 1,100,000 Units for ABVC BioPharma, Inc. PR Newswire
Aug-03-21 08:30AM	ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering GlobeNewswire -39.60%
Jun-09-21 10:20AM	ABVC: Enhancing Financial Flexibility To Support Growth Strategy Zacks Small Cap Research
Jan-27-21 04:55AM	ABVC: Developing a Growing Portfolio Of Plant-Based Therapies With Strong Prospects Zacks Small Cap Research
Jan-06-21 09:00AM	American BriVision Issues Shareholder Letter Outlining Achievements of 2020 and Outlook for 2021 GlobeNewswire
Nov-09-20 09:00AM	American BriVision Issues Clinical Study Report for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD) GlobeNewswire -31.25%
Sep-09-20 09:00AM	American BriVision Issues Clinical Study Report for Vitargus First-in-Human Phase I Clinical Trial GlobeNewswire -5.06%
Aug-24-20 09:00AM	American BriVision Announces New Patent Filed for Treatment of Major Depressive Disorder GlobeNewswire

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience